Work

Ruxolitinib in CMML: A Case Study of Innovative Trial Design in a Rare Cancer

Year: 2021

Type: article

Abstract: Alternative statistical designs cannot fully mitigate the limitations of traditional clinical trials in rare cancers. Creative study designs that integrate early clinical data and correlative outcomes from concomitant translational and laboratory models to evaluate the efficacy of druggable targets can potentially expedite access to novel therapies for these patients. See related article by Hunter et al., p. 6095

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-21-2578

Authors: Aditi Shastri, Diego A. Adrianzen-Herrera

Institutions: Albert Einstein College of Medicine, Montefiore Medical Center, University of Vermont

Language: English

Topic: Statistical Methods in Clinical Trials

Subfield: Statistics and Probability

Field: Mathematics

Domain: Physical Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3199645068